Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell-Reference-Cited by-同舟云学术

Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell

Published:2021-02-24 Issue:9 Volume:143 Page:3416-3429
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Knerr Laurent¹^ORCID,Prakash Thazha P.²^ORCID,Lee Richard²,Drury III William J.¹,Nikan Mehran²,Fu Wuxia²,Pirie Elaine²,Maria Leonardo De³^ORCID,Valeur Eric¹^ORCID,Hayen Ahlke¹,Ölwegård-Halvarsson Maria¹,Broddefalk Johan¹,Ämmälä Carina⁴,Østergaard Michael E.²,Meuller Johan⁵,Sundström Linda⁵,Andersson Patrik⁶,Janzén David⁷,Jansson-Löfmark Rasmus⁷,Seth Punit P.²,Andersson Shalini⁸

Affiliation:

1. Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

2. Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, California 92010, United States

3. Medicinal Chemistry, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

4. Bioscience, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

5. Mechanistic Biology & Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden

6. Respiratory and Immunology Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden

7. DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

8. Research and early Development, Discovery Sciences,, AstraZeneca, Gothenburg, Sweden

Publisher

American Chemical Society (ACS)

Subject

Colloid and Surface Chemistry,Biochemistry,General Chemistry,Catalysis

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.0c12043

Reference49 articles.

1. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

2. RNA-Targeted Therapeutics

3. Selective tissue targeting of synthetic nucleic acid drugs

4. Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver

5. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemically Modified Platforms for Better RNA Therapeutics;Chemical Reviews;2024-01-29

2. Safety and Tolerability of GalNAc₃-Conjugated Antisense Drugs Compared to the Same-Sequence 2′-O-Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data;Nucleic Acid Therapeutics;2024-01-16

3. Conjugation with glucagon like peptide-1 enables targeted protein degradation;Bioorganic Chemistry;2023-12

4. Synthesis of peptide–siRNA conjugates via internal sulfonylphosphoramidate modifications and evaluation of their in vitro activity;Nucleic Acids Research;2023-11-16

5. Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins;Journal of the American Chemical Society;2023-10-30